thyroxine and mgl-3196

thyroxine has been researched along with mgl-3196 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chabot-Blanchet, M; Chiang, E; Guertin, MC; Kelly, MJ; Reeves, RA; Tardif, JC; Taub, R	1

Trials

1 trial(s) available for thyroxine and mgl-3196

Article	Year
Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist. Atherosclerosis, 2013, Volume: 230, Issue:2 Topics: Adult; Body Mass Index; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Healthy Volunteers; Humans; Hypercholesterolemia; Liver; Male; Middle Aged; Patient Safety; Pyridazines; Thyroid Gland; Thyroid Hormone Receptors beta; Thyrotropin; Thyroxine; Time Factors; Triiodothyronine; Uracil	2013

Article

Year

Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist.

Atherosclerosis, 2013, Volume: 230, Issue:2

Topics: Adult; Body Mass Index; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Healthy Volunteers; Humans; Hypercholesterolemia; Liver; Male; Middle Aged; Patient Safety; Pyridazines; Thyroid Gland; Thyroid Hormone Receptors beta; Thyrotropin; Thyroxine; Time Factors; Triiodothyronine; Uracil

2013